EVQLV has launched Abtique, an online marketplace where scientists can order synthesis-ready, AI-designed antibody sequences in minutes. Abtique gives researchers direct access without building internal AI tools or contracting CROs. The platform is independently validated across dozens of labs and detailed in a new research paper.
NEW YORK, Dec. 2, 2025 /PRNewswire-PRWeb/ -- EVQLV announced the launch of Abtique, an online marketplace where scientists can order synthesis-ready antibody sequences directly from the Abtique website in minutes. The debut coincides with the release of HyperBind2, EVQLV's AI antibody design system, which uses machine learning models informed by experimental results to design antibody sequences with high predicted binding performance.
HyperBind2 has been independently validated in dozens of labs and detailed in a new research paper. Across its validation studies, HyperBind2 consistently produced binders across diverse antibody families and targets that matched or exceeded the affinities achieved through traditional discovery workflows. These capabilities position Abtique within a rapidly expanding market for next-generation antibody discovery.
AI-driven antibody design meets growing market demand
Antibodies power many of the world's leading medicines for cancer, arthritis, asthma, and more. The antibody market reached $246 billion in 2024 and is projected to grow to $685 billion by 2034 (Towards Healthcare, 2025). As scientists, researchers, and drug developers seek faster, less expensive ways to develop drugs, AI-driven design is advancing significantly across the life sciences. Yet building and validating these technologies requires years of work, significant costs, and rare expertise. Abtique gives researchers direct access to computationally designed, lab-validated sequences without engaging a contract research organization or running internal AI workflows, and the resulting antibody sequences are synthesis-ready for use by any CRO or in-house laboratory.
"Abtique answers the question: Why can't every researcher working on groundbreaking science access AI-designed molecules?" said Brett Averso, CTO of EVQLV. "With Abtique, a scientist can order ready-to-use antibody sequences in minutes, with no AI expertise required, backed by independent lab validation."
Independent validation and partner results in real-world settings
EVQLV's technology has been used in 48 projects across biopharma, diagnostics companies, leading academic labs, and large pharmaceutical companies. Early partners have designed antibodies targeting cancer, Alzheimer's, Parkinson's, MERS, and more.
Researchers collaborating with EVQLV have reported meaningful performance improvements across diverse targets. "Working with EVQLV streamlined our antibody development," said Professor Salvador Ventura, Director of the Institute of Research and Innovation Parc Taulí in Barcelona. "I've been working in protein design for more than 20 years, and this is one of the most remarkable examples of antibody-to-target design I've seen in my career. Their technology clearly made the difference in turning a challenging idea into a successful result."
"With the positive results we've seen from independent labs, we're excited to make validated AI-powered antibody design accessible to every researcher," said Andrew Satz, co-founder and CEO of EVQLV. "Our goal is to get better antibody designs into the hands of scientists to advance therapeutic innovation. This aligns with our mission to accelerate the speed at which healing reaches those in need."
About Abtique
Abtique is the first online storefront for AI-designed molecules. Built by EVQLV, Abtique offers a simple "click-to-sequence" experience that helps scientists and drug discovery teams use advanced AI-powered antibody design without building their own AI systems or learning complex software. The platform makes validated AI antibody design accessible to any lab and accelerates early-stage drug discovery workflows by delivering synthesis-ready sequences on demand. Visit the Abtique platform to learn more.
About EVQLV Inc.
EVQLV designs and engineers antibodies using advanced computational methods for life-science researchers at biotechs, academic labs, and pharmaceutical companies. Its computational antibody engineering technologies integrate machine learning with structural biology and experimental feedback loops. EVQLV operates in New York City and Miami. The company's mission is to help new antibody medicines reach patients faster. Learn more about EVQLV's computational antibody design technology.
Media Contact
Alexander Sonneborn
EVQLV Inc.
Media Contact
Alex Sonneborn, EVQLV, 1 9542812799, [email protected], https://evqlv.com
SOURCE EVQLV
Share this article